If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value right now, this article walks through the key signals that matter for long term investors. The stock has ...
The BioMarin Pharmaceutical Inc. acquisition of Amicus Therapeutics, Inc. will likely be beneficial and accretive for both ...
Four healthcare groups have filed an amicus brief in opposition to Johnson & Johnson’s 340B rebate model, arguing the policy undermines federal law and threatens safety-net hospitals. The brief was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback